Enovis Corporation
- Open
- 24.39
- Day high
- 24.54
- Day low
- 22.84
- Prev close
- 24.59
- Volume
- 274K
- Mkt cap
- $1.3B
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 0.9
- P/S
- 0.6
- Yield
- —
- Per share
- —
- ▲Insiders net buying $70K over the last 3 months (4 open-market buys, 0 sales)
- 🏛Institutions accumulating (13F)
Enovis Corporation (ENOV) is a Industrials company listed on NYSE. The stock is down 20% over the past year. Over the trailing 3 months, insiders filed 4 open-market buys and 0 sales (SEC Form 4).
Enovis Corporation (ENOV) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 5 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
ENOV earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Aug 6, 2026 | $0.85 | $0.90 | +6.3% | $583M | +0.2% |
| May 7, 2026 | $0.82 | $0.89 | +8.5% | $589M | +3.0% |
| Feb 26, 2026 | $0.79 | $0.95 | +20.6% | $576M | -1.2% |
| Nov 6, 2025 | $0.67 | $0.75 | +11.9% | $549M | -6.1% |
| Aug 7, 2025 | $0.74 | $0.79 | +6.8% | $565M | +4.8% |
| May 8, 2025 | $0.74 | $0.81 | +9.5% | $559M | +1.4% |
| Feb 26, 2025 | $0.92 | $0.98 | +6.5% | $561M | +2.4% |
| May 2, 2024 | $0.50 | $0.50 | +0.0% | $516M | +2.5% |
| Feb 22, 2024 | $0.76 | $0.79 | +3.9% | $455M | +2.2% |
| Aug 3, 2023 | $0.53 | $0.61 | +15.1% | $429M | +2.0% |
| May 4, 2023 | $0.37 | $0.44 | +18.9% | $406M | +3.8% |
| Feb 23, 2023 | $0.69 | $0.72 | +4.3% | $409M | -1.7% |
ENOV insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jul 1, 2026 | Ortiz Christinedirector | Grant | 846 | — |
| Jun 16, 2026 | Engert Oliverofficer: Chief Administrative Officer | Grant | 1,000 | $20.99 |
| Jun 16, 2026 | Engert Oliverofficer: Chief Administrative Officer | Buy | 1,000 | $20.92 |
| Jun 15, 2026 | Engert Oliverofficer: Chief Administrative Officer | Buy | 1,000 | $21.75 |
| Jun 15, 2026 | Engert Oliverofficer: Chief Administrative Officer | Buy | 200 | $20.99 |
| Jun 11, 2026 | Engert Oliverofficer: Chief Administrative Officer | Buy | 1,000 | $23.00 |
| Jun 3, 2026 | Engert Oliverofficer: Chief Administrative Officer | Buy | 1,000 | $22.22 |
| May 21, 2026 | Ortiz Christinedirector | Grant | 9,346 | — |
| May 21, 2026 | Bodem Barbara W.director | Grant | 9,346 | — |
| May 21, 2026 | Okala Philipdirector | Grant | 9,346 | — |
| May 21, 2026 | Shirley Bradydirector | Grant | 9,346 | — |
| May 21, 2026 | Kelly Liamdirector | Grant | 9,346 | — |
| May 21, 2026 | PERFALL A CLAYTONdirector | Grant | 9,346 | — |
| May 21, 2026 | Vinnakota Rajivdirector | Grant | 9,346 | — |
| May 21, 2026 | Wienbar Sharon Ldirector | Grant | 9,346 | — |
Source: ENOV SEC Form 4 filings, latest Jul 1, 2026. For informational purposes only — not investment advice.
See the full ENOV insider & 13F page →Enovis Corporation company profile
Overview
Enovis Corporation (NYSE:ENOV) is a medical technology company that emerged from a strategic transformation of Colfax Corporation in 2022. The company operates as a focused medical device manufacturer serving the orthopedic and musculoskeletal treatment market worldwide. Enovis develops, manufactures, and distributes medical products used by orthopedic specialists, surgeons, physical therapists, and other healthcare professionals to treat patients with conditions ranging from degenerative diseases to sports injuries. The company has grown significantly through strategic acquisitions, most notably the Lima Corporate acquisition in 2024, which substantially expanded its reconstructive joint surgery capabilities.
Business
Enovis operates in the medical device industry, specifically focusing on musculoskeletal healthcare solutions. The company serves the orthopedic market, which addresses conditions affecting bones, joints, muscles, ligaments, and tendons. This market includes both surgical interventions for joint replacement and non-surgical treatments for injury recovery and pain management. The company operates through two primary business segments: 1. Reconstruction (Recon) Segment - Representing approximately 60% of total revenue based on recent quarters. This segment manufactures and sells surgical implants and related products for joint replacement procedures. Products include hip implants, knee implants, shoulder systems, and extremity devices for foot, ankle, elbow, and finger reconstruction. The segment also includes advanced surgical navigation technology through the ARVIS platform, which provides augmented reality guidance for surgeons during procedures. These products are used in hospitals and ambulatory surgical centers when patients require joint replacement due to arthritis, trauma, or other degenerative conditions. 2. Prevention & Recovery (P&R) Segment - Representing approximately 40% of total revenue. This segment focuses on non-surgical treatment solutions including rigid and soft orthopedic braces, hot and cold therapy products, bone growth stimulators, compression garments, therapeutic shoes and inserts, and electrical stimulation devices for pain management. These products are used by healthcare professionals and patients for injury prevention, post-surgical recovery, and chronic condition management. The segment serves a broader market including physical therapy clinics, retail pharmacies, and direct-to-consumer channels. The orthopedic device market serves an aging population with increasing rates of joint degeneration, sports-related injuries, and trauma cases. Joint replacement procedures are typically performed when conservative treatments fail, making this a critical healthcare need with consistent demand patterns.
Revenue model
Enovis generates revenue primarily through product sales to healthcare providers, distributors, and retail channels. The company's business model operates on different revenue streams across its two segments. In the Reconstruction segment, Enovis sells high-value surgical implants and instruments directly to hospitals, ambulatory surgical centers, and orthopedic surgeons. These products command premium pricing due to their critical nature in surgical procedures and the specialized engineering required. The company also generates recurring revenue from surgical instruments, navigation technology licensing, and replacement components. Revenue is typically recognized upon product delivery, with some customers operating under consignment arrangements where payment occurs when products are used in surgery. The Prevention & Recovery segment operates through multiple channels including direct sales to healthcare professionals, distribution through independent distributors, consumer retail stores, and pharmacies. This segment includes both one-time product sales and recurring revenue from replacement components and consumable therapy products. The P&R business benefits from broader market reach and more predictable demand patterns compared to surgical products. Several factors influence the company's margins and profitability. Positive margin drivers include the premium pricing power of innovative surgical products, cross-selling opportunities from the expanded product portfolio following acquisitions, international market expansion where the company can command higher margins, and operational synergies from acquisition integration. The company's focus on ambulatory surgical centers also provides margin benefits as these facilities often prefer efficient, cost-effective solutions. Margin pressures come from healthcare cost containment initiatives that pressure device pricing, particularly in the reconstruction segment where hospitals negotiate aggressively. Supply chain disruptions and tariff exposure, particularly from Chinese suppliers, create cost headwinds. The company faces integration costs from recent acquisitions and competitive pricing pressure in mature product categories. Currency fluctuations also impact international operations, and the company must continuously invest in research and development to maintain technological competitiveness.
Competitive moat
Enovis operates in a medical device industry with moderate competitive moats built primarily around regulatory barriers, customer relationships, and specialized manufacturing capabilities. The company's strongest moat elements include FDA regulatory approvals and international certifications that create significant barriers to entry for new competitors. These regulatory processes can take years and cost millions of dollars, protecting established players like Enovis. The company benefits from switching costs in the reconstruction segment, where surgeons develop familiarity and expertise with specific implant systems and are reluctant to change platforms. This creates customer stickiness, particularly when combined with comprehensive training programs and surgical support services. The ARVIS navigation technology platform also creates some technological differentiation and recurring revenue potential. However, Enovis faces significant competitive challenges that limit its moat strength. The orthopedic device market is dominated by much larger competitors including Johnson & Johnson (DePuy Synthes), Stryker, and Zimmer Biomet, which have substantially greater resources for research and development, broader product portfolios, and stronger hospital relationships. These larger competitors can leverage economies of scale and comprehensive product suites that Enovis cannot match. The company's moat is relatively narrow compared to industry leaders. In the Prevention & Recovery segment, many products face competition from lower-cost alternatives and have limited differentiation. The acquisition of Lima Corporate has strengthened the reconstruction portfolio, but Enovis remains a mid-tier player without the market dominance or technological leadership of top-tier competitors. The company's success depends more on execution, niche market focus, and operational efficiency rather than insurmountable competitive advantages. Disruption risks include new surgical techniques, alternative treatment modalities, and potential consolidation among larger competitors that could further pressure market share.
Risks & safety
The company presents moderate financial risk with several areas of concern regarding margin of safety. • Cash and Liquidity: Low cash position of $38.4 million against current liabilities of $477.4 million creates liquidity concerns. Current ratio of 2.55 provides some buffer, but quick ratio of 1.32 indicates inventory-heavy working capital. • Debt and Solvency: Debt-to-equity ratio of 0.56 is manageable but elevated following Lima acquisition. Company targets reducing leverage to low 3x EBITDA levels. Free cash flow of -$44.9 million in Q1 2025 indicates cash burn, though management expects positive free cash flow for full year. • Profitability Concerns: Net losses in recent quarters (-$55.7 million Q1 2025) despite positive EBITDA of $23.3 million. Negative return on equity of -2.1% indicates poor shareholder returns. • Valuation Metrics: EV/EBITDA of 35.1x appears elevated, though distorted by integration costs. Price-to-book ratio of 0.71 suggests potential undervaluation relative to assets. • Other Considerations: Tariff exposure of $40 million with mitigation plans, CEO transition creating leadership uncertainty, and integration risks from Lima acquisition ongoing.
Recent development
Over the past few years, Enovis has undergone significant strategic transformation and expansion. The most significant development was the acquisition of Lima Corporate in January 2024, which substantially expanded the company's reconstruction capabilities and international presence. This $1 billion acquisition added complementary hip, knee, and extremity products while providing stronger European market access. The integration has progressed ahead of schedule, with management reporting revenue synergies and successful sales force consolidation. The company has focused heavily on innovation and new product launches across both segments. Key developments include the ARVIS 2.0 augmented reality surgical navigation platform, which provides surgeons with real-time guidance during joint replacement procedures. In the reconstruction segment, Enovis launched the EMPOWR revision knee system, AltiVate reverse shoulder systems, and expanded extremity offerings including foot and ankle solutions. The Prevention & Recovery segment introduced next-generation bracing products and advanced electrotherapy devices. Operational improvements have been a major focus, with the company implementing its EGX business system to drive continuous improvement and cost reduction. Management achieved $25 million in fixed cost reductions while expanding EBITDA margins by over 200 basis points in recent periods. The company has also been addressing supply chain challenges, particularly tariff mitigation strategies to reduce exposure to Chinese suppliers and diversify sourcing to other countries. Leadership transition represents another significant development, with CEO Matthew Trerotola announcing his retirement in 2025. The board is conducting a search for new leadership while maintaining strategic continuity. The company has also been preparing for potential market expansion through cross-selling opportunities, leveraging the broader product portfolio across different geographic markets and customer segments.
ENOV company profile · for informational purposes only — not investment advice.
Track ENOV with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free